Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

Epigenomics. 2019 Jun;11(8):885-897. doi: 10.2217/epi-2018-0159. Epub 2019 Jun 6.

Abstract

Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.

Keywords: ABCG1; DNA methylation; EWAS; SREBF1; Type 2 diabetes; blood; liver; visceral adipose tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 1 / genetics*
  • DNA Methylation
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / genetics*
  • Genetic Markers / genetics
  • Humans
  • Insulin / metabolism
  • Sterol Regulatory Element Binding Protein 1 / genetics*

Substances

  • ABCG1 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 1
  • Genetic Markers
  • Insulin
  • SREBF1 protein, human
  • Sterol Regulatory Element Binding Protein 1